A 6-Week Open Label Cross-Over Study With 2 Different Daily Doses of Minirin Oral Lyophilisate (120 microg and 240 microg) and 2 Different Daily Doses of Minirin Tablet (0.2 mg and 2 x 0.2 mg) in Children and Adolescents With Primary Nocturnal Enuresis (PNE).

Trial Profile

A 6-Week Open Label Cross-Over Study With 2 Different Daily Doses of Minirin Oral Lyophilisate (120 microg and 240 microg) and 2 Different Daily Doses of Minirin Tablet (0.2 mg and 2 x 0.2 mg) in Children and Adolescents With Primary Nocturnal Enuresis (PNE).

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 May 2011

At a glance

  • Drugs Desmopressin (Primary)
  • Indications Enuresis
  • Focus Therapeutic Use
  • Acronyms PALAT
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 25 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top